U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) rose sharply during Thursday's session.
Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
Enliven Therapeutics shares surged 26% to $24.97 on Thursday.
Here are some other big stocks recording losses in today's session.
- Rallybio Corporation (NASDAQ:RLYB) shares gained 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) jumped 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.
- Janux Therapeutics, Inc. (NASDAQ:JANX) shares jumped 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.
- Gyre Therapeutics, Inc. (NASDAQ:GYRE) rose 14.6% to $15.91.
- AnaptysBio, Inc. (NASDAQ:ANAB) rose 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.
- Fiverr International Ltd. (NYSE:FVRR) gained 10.5% to $21.25 after the company's board authorized a $100 million share repurchase program.
- GigaCloud Technology Inc. (NASDAQ:GCT) shares jumped 10.2% to $34.18.
- Nurix Therapeutics, Inc. (NASDAQ:NRIX) climbed 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.
- AlTi Global, Inc. (NASDAQ:ALTI) gained 9.3% to $5.06.
- Nexxen International Ltd. (NASDAQ:NEXN) rose 7.3% to $5.62.
- StepStone Group LP (NASDAQ:STEP) gained 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.
- Frontline plc (NYSE:FRO) rose 5.9% to $24.47.
- IAMGOLD Corporation (NYSE:IAG) gained 3.6% to $3.74.
Now Read This: Dell, Designer Brands And 2 Other Stocks Insiders Are Selling